Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | Chief Marketing Officer | February 16, 2022 | February 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date February 16, 2022 · Filed February 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,168 |
Reported balance
After 2022-02-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-16 · Tax withholding · Disposed 6,389 · Balance 35,168 F1: The reporting person has elected to satisfy his tax withholding obligation in connection with the vesting of a prior restricted stock grant by directing the Company to withhold shares otherwise issuable upon vesting of the previously reported grant. F2: Includes 15,000 shares of restricted stock for which the risk of forfeiture will lapse as to 5,000 shares on each of 2/16/23, 2/16/24 and 2/16/25. |
| Stock Optoin (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.66 · Expires 2031-02-16 | Direct | 114,178 |
Reported balance
Holding disclosure · report date 2022-02-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 114,178 F3: Options to purchase 28,545 shares vest on 2/16/22 and options to purchase 85,633 shares vest quarterly in 12 equal amounts commencing on 5/16/22. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.47 · Expires 2031-09-01 | Direct | 57,368 |
Reported balance
Holding disclosure · report date 2022-02-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 57,368 F4: Options to purchase 14,342 shares vest on 9/1/22 and options to purchase 43,026 shares vest quarterly in 12 equal amounts commencing on 12/1/22. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person has elected to satisfy his tax withholding obligation in connection with the vesting of a prior restricted stock grant by directing the Company to withhold shares otherwise issuable upon vesting of the previously reported grant.
F2: Includes 15,000 shares of restricted stock for which the risk of forfeiture will lapse as to 5,000 shares on each of 2/16/23, 2/16/24 and 2/16/25.
F3: Options to purchase 28,545 shares vest on 2/16/22 and options to purchase 85,633 shares vest quarterly in 12 equal amounts commencing on 5/16/22.
F4: Options to purchase 14,342 shares vest on 9/1/22 and options to purchase 43,026 shares vest quarterly in 12 equal amounts commencing on 12/1/22.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2022 Filed Feb 18, 2022 22:03 UTC | NEPHROS INC NEPH · Entity 7279 | Tax withholdingCommon Stock | 6,389 | $4.80 | $30,667.20 |
DisclosureSEC source: 0001437749-22-003841 · rdgdoc.xml · nonDerivative · entry 1 Lobo Wesley S. · CIK 0001841597 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,168 F1 · shares: The reporting person has elected to satisfy his tax withholding obligation in connection with the vesting of a prior restricted stock grant by directing the Company to withhold shares otherwise issuable upon vesting of the previously reported grant. F2 · balance_after: Includes 15,000 shares of restricted stock for which the risk of forfeiture will lapse as to 5,000 shares on each of 2/16/23, 2/16/24 and 2/16/25. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:29 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 57,368 | $0.00 Strike: $8.47 | $0.00 |
DisclosureSEC source: 0000914190-21-000344 · edgar.xml · derivative · entry 3 Lobo Wesley S. · CIK 0001841597 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,368 Underlying: Common Stock · 57,368 shares Expires 2031-09-01 F3 · derivative.exercise_date: Options to purchase 14,342 shares vest on 9/1/22 and options to purchase 43,026 shares vest quarterly in 12 equal amounts commencing on 12/1/22. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 17:01 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 1,000 | $7.92 | $7,920.00 |
DisclosureSEC source: 0000914190-21-000286 · edgar.xml · nonDerivative · entry 1 Lobo Wesley S. · CIK 0001841597 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,557 F1 · balance_after: Includes (i) 20,557 shares of restricted stock for which the risk of forfeiture will lapse on 2/16/22; and (ii) 20,000 shares of restricted stock for which the risk of forfeiture will lapse as to 5,000 shares on each of 2/16/22, 2/16/23, 2/16/24 and 2/16/25. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:48 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Optoin (right to buy) · Derivative | 114,178 | $0.00 Strike: $8.66 | $0.00 |
DisclosureSEC source: 0000914190-21-000070 · edgar.xml · derivative · entry 2 Lobo Wesley S. · CIK 0001841597 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,178 Underlying: Common Stock · 114,178 shares Expires 2031-02-16 F2 · derivative.exercise_date: Options to purchase 28,545 shares vest on 2/16/22 and options to purchase 85,633 shares vest quarterly in 12 equal amounts commencing on 5/16/22. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:48 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 40,557 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000070 · edgar.xml · nonDerivative · entry 1 Lobo Wesley S. · CIK 0001841597 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,557 F1 · shares: Includes (i) 20,557 shares of restricted stock for which the risk of forfeiture will lapse on 2/16/22; and (ii) 20,000 shares of restricted stock for which the risk of forfeiture will lapse as to 5,000 shares on each of 2/16/22, 2/16/23, 2/16/24 and 2/16/25. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.